Shanghai Henlius Biotech logo

Shanghai Henlius Biotech(SEHK) 2696

Market CapHK$28.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+8%
5 Year+102%
1 Year-27%
1 Month-14%
HK$49.90
-2.92%
-1.50Today
Shanghai Henlius Biotech last closing stock price
MetricPriceDate
Last closeHKD 51.002026-10-15
Shanghai Henlius Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.69%HKD 50.652026-10-08
1 month-13.92%HKD 59.252026-09-15
3 month-11.69%HKD 57.752026-07-17
Year to date-10.6%HKD 57.052025-12-31
1 year-27.35%HKD 70.202025-10-15
3 year+378.42%HKD 10.662023-10-16
5 year+101.98%HKD 25.252021-10-15
Since inception+7.99%HKD 49.452019-09-25

Shanghai Henlius Biotech Financials at a Glance

Market Cap

HK$28.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥7.44B

Net Income (TTM)

CN¥867.35M

EPS (TTM)

HK$1.77

P/E Ratio

28.87

Dividend

HK$0.00

Beta (Volatility)

-0.11 (Low)

Price

HK$49.90

Volume

1,516,900

Open

HK$50.10

Previous Close

HK$51.40

Daily Range

HK$49.40 - HK$51.95

52-Week Range

HK$47.62 - HK$87.10

Estimated Earnings Date

Mar 19, 2027

2696 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. is a biopharmaceutical enterprise focused on the research and development of biologic medicines, primarily targeting cancer, autoimmune conditions, and ophthalmic disorders. The company has a diverse portfolio of approved biologic treatments and a robust pipeline of investigational compounds.

Products and Services
  • HANLIKANG: Rituximab injection for non-Hodgkin lymphoma and rheumatoid arthritis
  • HANQUYOU: Trastuzumab injection for breast and gastric cancer
  • HANDAYUAN: Adalimumab injection for various autoimmune diseases
Growth Outlook
  • Strong pipeline with multiple investigational compounds targeting solid tumors
  • Expansion into international markets enhances growth potential
  • Recent approvals and ongoing trials may drive future revenue growth
Financial Highlights
  • Q2 2026 revenue of 1.79 billion CNY, reflecting consistent performance
  • Net income of 215 million CNY in Q2 2026, indicating profitability
  • Gross profit margin of 77.15% in Q2 2026, showcasing operational efficiency
Shanghai Henlius Biotech, Inc. operates in a competitive biotechnology sector, leveraging its innovative research capabilities to develop treatments for serious health conditions. The company's focus on biologic medicines positions it well to capitalize on the growing demand for advanced therapies. With a strong financial performance and a promising pipeline, Shanghai Henlius is poised for continued growth in the biopharmaceutical landscape.
AI Generated • Oct 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,762

CEO

Jun Zhu, EMBA

Website

www.henlius.com

Headquarters

Shanghai, SH 200233, CN

2696 Financials

Key Financial Metrics (TTM)

Gross Margin

74.69%

Operating Margin

12.06%

Net Income Margin

11.67%

Return on Equity

20.41%

Return on Capital

10.81%

Return on Assets

6.62%

Earnings Yield

3.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$28.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

545.30M

Volume

1.52M

Avg. Volume

972.24K

Financials (TTM)

Gross Profit

CN¥5.55B

Operating Income

CN¥896.46M

EBITDA

CN¥1.27B

Operating Cash Flow

CN¥814.46M

Capital Expenditure

-CN¥174.51M

Free Cash Flow

CN¥639.95M

Cash & ST Invst.

CN¥956.03M

Total Debt

CN¥3.95B

Shanghai Henlius Biotech Performance Analysis

Shanghai Henlius Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 3,738,339,42984.4%
20232023-12-31CNY 5,961,363,64059.5%
20242024-12-31CNY 6,206,584,0914.1%
20252025-12-31CNY 7,230,112,78516.5%
Shanghai Henlius Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3036.4%
Q42025-12-31N/A
Q12026-03-31-6.7%
Q22026-06-30N/A
Shanghai Henlius Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -1.49-32.2%
20232023-12-31CNY 1.11N/A
20242024-12-31CNY 1.6448.1%
20252025-12-31CNY 1.640.4%
Shanghai Henlius Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.3%
Q42025-12-312.6%
Q12026-03-31-2.5%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.79B

+27.3%

Gross Profit

CN¥1.38B

+26.3%

Gross Margin

77.15%

N/A

Market Cap

HK$28.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$6.87M

N/A

Employees

4,082

N/A

Net Income

CN¥215.22M

+10.3%

EBITDA

CN¥339.87M

+4.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥956.03M

-1.7%

Total Debt

CN¥3.95B

+7.6%

Accounts Receivable

CN¥1.74B

+45.8%

Inventory

CN¥612.01M

-27.0%

Long Term Debt

CN¥1.68B

+54.5%

Short Term Debt

CN¥2.27B

-14.6%

Return on Assets

6.62%

N/A

Return on Invested Capital

10.67%

N/A

Free Cash Flow

CN¥243.25M

-18.6%

Operating Cash Flow

CN¥279.71M

-27.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 2696

What is the current price of Shanghai Henlius Biotech?

Shanghai Henlius Biotech is trading at HK$49.90 per share.

What is the 52-week range for Shanghai Henlius Biotech?

Over the past 52 weeks, Shanghai Henlius Biotech has traded between HK$47.62 and HK$87.10.

How much debt does Shanghai Henlius Biotech have?

As of the most recent reporting period, Shanghai Henlius Biotech reported total debt of CN¥4.01B.

How much cash does Shanghai Henlius Biotech have on hand?

Shanghai Henlius Biotech reported CN¥645.13M in cash and cash equivalents in its most recent financial results.

What is Shanghai Henlius Biotech’s dividend yield?

Shanghai Henlius Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services